NASDAQ:GNPX
Genprex Inc. Stock News
$2.26
-0.0100 (-0.441%)
At Close: May 01, 2024
Genprex to Present and Participate at Upcoming May Investor and Industry Conferences
08:31am, Wednesday, 01'st May 2024
AUSTIN, Texas , May. 1, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up
10:01am, Thursday, 04'th Apr 2024
Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.
Genprex to Present at Upcoming BIO CEO & Investor Conference
07:30am, Tuesday, 06'th Feb 2024
Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Feb. 6, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene
Acclaim-1 Phase 1 study had no Dose Limiting Toxicity, and results establish Phase 2 Recommended Dose as well as provide data showing efficacy of REQORSA® in combination with Tagrisso® Preclinical r
GENPREX (GNPX) Upgraded to Buy: Here's What You Should Know
01:32pm, Monday, 04'th Sep 2023
GENPREX (GNPX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Genprex granted Chinese patent for lead drug candidate REQORSA with PD-1 antibodies to treat cancers
09:47am, Wednesday, 05'th Jul 2023
Genprex Inc. revealed that the China National Intellectual Property Administration has granted it a broad patent, which covers the use of its lead drug candidate REQORSA Immunogene therapy, in combina
Genprex shares rise as FDA grants third Fast Track Designation for small cell lung cancer therapeutic REQORSA
09:31am, Wednesday, 28'th Jun 2023
Genprex, Inc. (NASDAQ:GNPX) shares moved higher in pre-market trading after the clinical-stage gene therapy company announced that the US Food and Drug Administration (FDA) has granted Fast Track Desi
Genprex (GNPX) Up on Advancing Early-Stage NSCLC Study
01:05pm, Thursday, 01'st Jun 2023
Genprex's (GNPX) shares rise due to the advancement of early-stage Acclaim-1 study for patients with late-stage non-small cell lung cancer.
Genprex Inc. revealed that it has completed the Phase 1 portion of the Acclaim-1 Phase 1/2 clinical trial evaluating REQORSA Immunogene therapy combined with Tagrisso in late-stage non-small cell lun
Genprex says positive data from Acclaim-1 clinical trial to be published at 2023 ASCO meeting
08:06am, Friday, 26'th May 2023
Genprex Inc. (NASDAQ:GNPX) said positive data from the Phase 1 portion of its Acclaim-1 clinical trial evaluating REQORSA Immunogene Therapy in combination with Tagrisso in late-stage non-small cell l
Penny Stocks To Buy? 10 Under $1 To Watch This Week
03:29pm, Wednesday, 19'th Apr 2023
Penny stocks under $1 to watch this week. The post Penny Stocks To Buy?
Genprex showcases unique potential of nonparticle delivery system at cancer conference; shares rise
11:14am, Wednesday, 19'th Apr 2023
A research collaborator of Genprex Inc delivered a presentation highlighting the company's non-viral ONCOPREX Nanoparticle Delivery System, the company announced. Investors liked what they saw, as sh
Genprex encouraged by latest reports on novel tumor suppressor
11:06am, Tuesday, 18'th Apr 2023
Genprex, Inc. (NASDAQ:GNPX) said independent researchers have reported that the tumor suppression gene used in its lead drug candidate REQORSA functions as a novel tumor suppressor for glioblastoma. G
Genprex to Present at Bioprocessing Summit Conference
07:30am, Monday, 13'th Mar 2023
Genprex Chief Manufacturing and Technology Officer to Provide Insight on Manufacturing Gene Therapies AUSTIN, Texas , March 13, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:
Genprex announces $4M direct offering with single, healthcare-focused institutional investor
09:12am, Monday, 27'th Feb 2023
Genprex Inc. said it has entered into a securities purchase agreement with a single, healthcare-focused institutional investor for gross proceeds of approximately $4 million.